The Role of Microparticles as a Biomarker in Distinguishing Between Thrombotic Thrombocytopenic Purpura (TTP) and Atypical Hemolytic Uremic Syndrome (aHUS)
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- Microparticle/Nanoparticle number (an absolute number)
研究概览
简要总结
The investigators propose to characterize MPs in aHUS and TTP both at the onset and throughout treatment. The investigators believe that the number, size, and cell origin of MPs will differ between these two diseases. The hypothesis is that endothelial derived MPs will be higher in number and comprise a larger portion of the MP population in aHUS and that platelet MPs will comprise a larger number and greater proportion of MPs in TTP. The investigators believe that MP identity and number can be used to reliably differentiate between aHUS and TTP at disease onset.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 120 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with MAHA, TTP, and/or aHUS
排除标准
- •Prisoners
结局指标
主要结局
Microparticle/Nanoparticle number (an absolute number)
时间窗: an average of 3 months
Microparticle/Nanoparticle size (in nanometers or micrometers)
时间窗: an average of 3 months
Microparticle/Nanoparticle identity (identity of cell type from which they are derived)
时间窗: an average of 3 months
次要结局
- Morbidities(3 months)
- Mortality(3 months)
研究者
Majed Refaai
Associate Professor
University of Rochester